B
Chinese BCI company developing non-invasive and invasive brain-computer interface medical devices, including EEG acquisition systems, transcranial electrical stimulation devices, and the NEO-ONE SCI invasive BCI.
$350MIPO
Investor undisclosed
A $350M IPO for a Chinese BCI company signals that invasive neural interfaces are moving from research curiosity to regulated medical product—the bar for going public on hardware this complex is high. If you're building in neurotech, adjacent biodevices, or clinical software, watch how Boruikang navigates FDA/CE approval timelines and reimbursement; Chinese regulatory wins often preview what Western markets will accept 18-24 months later.